ZyHMG 150iu Injection (Menotrophin (HMG))

Product Overview

ZyHMG 150iu injection is a pharmaceutical formulation that contains Menotrophin, a purified human menopausal gonadotropin (HMG) derived from the urine of post‑menopausal women. Each sterile vial provides 150 international units of gonadotropin activity and is supplied together with a separate ampoule of sterile sodium chloride (NaCl) solution for reconstitution. The product is manufactured by German Remedies Private Ltd and is indicated for the treatment of female infertility associated with anovulation or oligoovulation, as well as male hypogonadism and related infertility conditions. Proper storage at 2–8°C and protection from light are required until use.

What is ZyHMG 150iu Injection (Menotrophin (HMG))?

Menotrophin consists of a heterogeneous mixture of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity. In clinical practice it acts as a substitute for endogenous gonadotropins, stimulating the ovaries in women and supporting testosterone production in men. The 150iu strength is the most commonly prescribed dose for ovulation induction and for stimulating spermatogenesis when a physician determines that hormonal replacement is appropriate.

Uses and Benefits

The therapeutic uses of ZyHMG fall into two main categories:

• Female infertility: It is employed to induce ovulation in women with polycystic ovary syndrome (PCOS), unexplained infertility, or other anovulatory disorders. When combined with timed intercourse or assisted reproductive techniques such as intrauterine insemination (IUI) or in‑vitro fertilisation (IVF), Menotrophin can increase the number of mature follicles and improve pregnancy rates.
• Male hypogonadism and infertility: In men with secondary hypogonadism, the medication can restore endogenous testosterone secretion and, in some cases, improve sperm production. This is particularly useful when low gonadotropin levels are confirmed by laboratory testing.

Clinical benefits reported in peer‑reviewed studies include more regular menstrual cycles, higher embryo implantation rates in IVF cycles, and improved serum testosterone concentrations in hypogonadal men. These outcomes contribute to better reproductive health and can reduce the need for more aggressive or costly interventions.

How It Works

After reconstitution, Menotrophin binds to FSH and LH receptors on ovarian granulosa cells and on Leydig cells in the testes. In the ovary, this interaction promotes the growth of multiple follicles, enhances estrogen production, and prepares the endometrium for potential implantation. In the male reproductive system, the LH‑like activity stimulates Leydig cells to synthesize testosterone, which in turn supports spermatogenesis in the seminiferous tubules. The dual‑hormonal activity makes Menotrophin a versatile agent for both ovulation induction and androgen replacement in selected male patients.

Dosage Guidelines

Dosage must always be individualized by a qualified healthcare professional and should follow the prescribing information provided by the manufacturer. Typical regimens are:

• Female infertility: A common starting dose is 75–150 IU administered daily for 3–6 consecutive days, usually beginning on day 2–3 of the menstrual cycle. Follicular development is monitored by transvaginal ultrasound, and the dose may be adjusted based on the response. If multiple follicles develop beyond a predefined threshold, the cycle may be canceled to reduce the risk of ovarian hyperstimulation syndrome (OHSS).
• Male hypogonadism: The usual dose is 150 IU administered intramuscularly or subcutaneously every 2–3 days for several weeks. Serum testosterone levels are checked at regular intervals, and the dose may be titrated upward or downward to maintain physiologic concentrations without causing supraphysiologic androgen exposure.

Reconstitution steps should be performed under aseptic conditions: the diluent is injected into the vial, the mixture is gently swirled until a clear solution is obtained, and the solution is used immediately or within the timeframe specified in the product leaflet. Patients should never reuse a vial after opening and should discard any unused portion according to local regulations.

Side Effects

Most adverse events are mild and relate to the injection site or transient hormonal fluctuations. Common side effects include:

• Local pain, redness, or swelling at the injection site.
• Headache, mild abdominal discomfort, or bloating.
• Nausea, fatigue, or temporary mood changes.

Although rare, clinicians should be alert for more serious complications such as ovarian hyperstimulation syndrome, which may present with rapid weight gain, shortness of breath, or decreased urine output, and for allergic reactions that could manifest as rash, itching, or difficulty breathing. Immediate medical attention is required if any of these symptoms occur.

Warnings and Precautions

Before initiating therapy, a comprehensive medical evaluation is essential. Important warnings include:

• Contraindication in patients with known hypersensitivity to Menotrophin or any excipient in the formulation.
• Use with caution in women who have ovarian cysts, pelvic inflammatory disease, or abnormal uterine bleeding that have not been evaluated.
• Potential for multiple gestation; patients should be counseled about the increased risk of twins or higher-order multiples.
• Interaction with hormonal contraceptives may alter cycle regularity; any concomitant hormonal therapy should be reviewed.
• Patients with a history of thromboembolic disorders should be monitored closely, as hormonal stimulation can theoretically increase clotting risk.
• Regular laboratory monitoring of serum estradiol in women and testosterone in men is recommended to guide dose adjustments and to detect early signs of over‑stimulation.

Storage conditions: keep the unopened vial refrigerated (2–8°C) and protect from light. Once reconstituted, the solution should be used promptly and any remaining product discarded after the indicated period or if it becomes cloudy or discolored.

Frequently Asked Questions

What distinguishes Menotrophin from recombinant follicle‑stimulating hormone?

Menotrophin is a urinary extract that contains a mixture of FSH and LH activities derived from post‑menopausal women, whereas recombinant FSH is a synthetically produced, single‑protein preparation that contains only FSH. The choice between the two depends on clinic protocols, patient response, and cost considerations.

Can ZyHMG be prescribed for weight loss or bodybuilding?

No. The therapeutic indication of ZyHMG is limited to reproductive hormonal stimulation. Using the drug for non‑approved purposes such as weight reduction or performance enhancement lacks scientific support and may pose health risks.

Is it safe to use ZyHMG during pregnancy?

ZyHMG is contraindicated in pregnant women. If pregnancy is suspected or confirmed during treatment, the medication should be stopped immediately and a healthcare provider consulted.

How should the injection be administered?

The vial is reconstituted with the supplied sterile NaCl diluent, gently swirled until clear, and then administered either intramuscularly or subcutaneously according to the physician’s dosing schedule. Proper injection technique and site rotation are important to minimize discomfort.

Where can I find authoritative scientific information about this medication?

Trusted sources include the National Center for Biotechnology Information, the U.S. Food and Drug Administration, and the MedlinePlus database, which provide detailed pharmacologic and safety data.